The Moderna coronavirus vaccine may provide a very high level of protection against Covid-19 and there does not appear to be any evidence that efficacy is worse in old age, primary analysis for the final phase of the study suggests.
The UK has received seven million doses of the vaccine from the US company – enough for about 3.5 million people in the UK.
Moderna said the analysis of the phase three COVE study of the vaccine candidate, called mRNA-1273, which involved 30,000 participants, included 196 cases of Covid-19, 30 of which were serious.
The vaccine efficacy against the disease was 94.1% and the vaccine efficacy against severe Covid-19 was 100%, the company reported.
It added that the jab is generally well tolerated with no serious safety concerns identified to date.
The study exceeded more than two months of median follow-up after vaccination.
Announcing the results on Monday, Moderna said it plans to apply for emergency use authorization from the U.S. Food and Drug Administration (FDA), to apply for conditional marketing authorization from the European Medicines Agency (EMA). ) and to continue with the ongoing reviews, which have already started with international regulators.